Huperzine A

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 600142

CAS#: 102518-79-6

Description: Huperzine A is an acetylcholinesterase inhibitor and NMDA receptor antagonist. Huperzine A is extracted from Huperzia serrata. Huperzine A has been investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer's disease. As of 2013 although some research suggests it may be helpful, the evidence overall is not convincing enough for it to be recommended for use as a medicine, and little is known of its safety. Huperzine A is also marketed as a dietary supplement with claims made for its ability to improve memory and mental function. (

Chemical Structure

Huperzine A
CAS# 102518-79-6

Theoretical Analysis

MedKoo Cat#: 600142
Name: Huperzine A
CAS#: 102518-79-6
Chemical Formula: C15H18N2O
Exact Mass: 242.14191
Molecular Weight: 242.32
Elemental Analysis: C, 74.35; H, 7.49; N, 11.56; O, 6.60

Price and Availability

Size Price Availability Quantity
200.0mg USD 550.0 2 Weeks
500.0mg USD 950.0 2 Weeks
1.0g USD 1650.0 2 Weeks
2.0g USD 2650.0 2 Weeks
5.0g USD 5650.0 2 Weeks
Bulk inquiry

Synonym: Huperzine A; Selagine; (-)-huperzine A; (-)-Selagine.

IUPAC/Chemical Name: (5S,9R,E)-5-amino-11-ethylidene-7-methyl-5,6,9,10-tetrahydro-5,9-methanocycloocta[b]pyridin-2(1H)-one.


InChi Code: InChI=1S/C15H18N2O/c1-3-11-10-6-9(2)8-15(11,16)12-4-5-14(18)17-13(12)7-10/h3-6,10H,7-8,16H2,1-2H3,(H,17,18)/b11-3+/t10-,15-/m0/s1

SMILES Code: O=C(N1)C=CC2=C1C[C@H]3/C([C@@]2(N)CC(C)=C3)=C\C

Appearance: solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 242.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Qian ZM, Ke Y. Huperzine A: Is it an Effective Disease-Modifying Drug for Alzheimer's Disease? Front Aging Neurosci. 2014 Aug 19;6:216. doi: 10.3389/fnagi.2014.00216. eCollection 2014. Review. PubMed PMID: 25191267; PubMed Central PMCID: PMC4137276.

2: Xing SH, Zhu CX, Zhang R, An L. Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis. Evid Based Complement Alternat Med. 2014;2014:363985. doi: 10.1155/2014/363985. Epub 2014 Feb 3. Review. PubMed PMID: 24639880; PubMed Central PMCID: PMC3930088.

3: Yang G, Wang Y, Tian J, Liu JP. Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One. 2013 Sep 23;8(9):e74916. doi: 10.1371/journal.pone.0074916. eCollection 2013. Review. PubMed PMID: 24086396; PubMed Central PMCID: PMC3781107.

4: Yue J, Dong BR, Lin X, Yang M, Wu HM, Wu T. Huperzine A for mild cognitive impairment. Cochrane Database Syst Rev. 2012 Dec 12;12:CD008827. doi: 10.1002/14651858.CD008827.pub2. Review. PubMed PMID: 23235666.

5: Ha GT, Wong RK, Zhang Y. Huperzine a as potential treatment of Alzheimer's disease: an assessment on chemistry, pharmacology, and clinical studies. Chem Biodivers. 2011 Jul;8(7):1189-204. doi: 10.1002/cbdv.201000269. Review. PubMed PMID: 21766442.

6: Hao Z, Liu M, Liu Z, Lv D. Huperzine A for vascular dementia. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007365. doi: 10.1002/14651858.CD007365.pub2. Review. PubMed PMID: 19370686; PubMed Central PMCID: PMC4171119.

7: Desilets AR, Gickas JJ, Dunican KC. Role of huperzine a in the treatment of Alzheimer's disease. Ann Pharmacother. 2009 Mar;43(3):514-8. doi: 10.1345/aph.1L402. Epub 2009 Feb 24. Review. PubMed PMID: 19240260.

8: Zhang HY, Zheng CY, Yan H, Wang ZF, Tang LL, Gao X, Tang XC. Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia. Chem Biol Interact. 2008 Sep 25;175(1-3):396-402. doi: 10.1016/j.cbi.2008.04.049. Epub 2008 May 13. Review. PubMed PMID: 18565502.

9: Li J, Wu HM, Zhou RL, Liu GJ, Dong BR. Huperzine A for Alzheimer's disease. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005592. doi: 10.1002/14651858.CD005592.pub2. Review. PubMed PMID: 18425924.

10: Little JT, Walsh S, Aisen PS. An update on huperzine A as a treatment for Alzheimer's disease. Expert Opin Investig Drugs. 2008 Feb;17(2):209-15. doi: 10.1517/13543784.17.2.209. Review. PubMed PMID: 18230054.

11: Li WM, Kan KK, Carlier PR, Pang YP, Han YF. East meets West in the search for Alzheimer's therapeutics - novel dimeric inhibitors from tacrine and huperzine A. Curr Alzheimer Res. 2007 Sep;4(4):386-96. Review. PubMed PMID: 17908041.

12: Zhang HY, Yan H, Tang XC. Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase. Cell Mol Neurobiol. 2008 Feb;28(2):173-83. Epub 2007 Jul 27. Review. PubMed PMID: 17657601.

13: Ma X, Tan C, Zhu D, Gang DR, Xiao P. Huperzine A from Huperzia species--an ethnopharmacolgical review. J Ethnopharmacol. 2007 Aug 15;113(1):15-34. Epub 2007 Jun 2. Review. PubMed PMID: 17644292.

14: Haviv H, Wong DM, Silman I, Sussman JL. Bivalent ligands derived from Huperzine A as acetylcholinesterase inhibitors. Curr Top Med Chem. 2007;7(4):375-87. Review. PubMed PMID: 17305579.

15: Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin. 2006 Jan;27(1):1-26. Review. PubMed PMID: 16364207.

16: Wang R, Tang XC. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease. Neurosignals. 2005;14(1-2):71-82. Review. PubMed PMID: 15956816.

17: Liu L, Sun JX. [Advances on study of organophosphate poisoning prevented by Huperzine A]. Wei Sheng Yan Jiu. 2005 Mar;34(2):224-6. Review. Chinese. PubMed PMID: 15952670.

18: Huperzine A. Drugs R D. 2004;5(1):44-5. Review. PubMed PMID: 14725492.

19: Jiang H, Luo X, Bai D. Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: a drug of traditional chinese medicine origin for the treatment of Alzheimer's disease. Curr Med Chem. 2003 Nov;10(21):2231-52. Review. PubMed PMID: 14529340.

20: Zangara A. The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacol Biochem Behav. 2003 Jun;75(3):675-86. Review. PubMed PMID: 12895686.

Additional Information

Huperzine A, is a naturally occurring sesquiterpene alkaloid found in the extracts of the firmoss Huperzia serrata. The botanical has been used in China for centuries for the treatment of swelling, fever and blood disorders. Recently in clinical trials in China, it has demonstrated neuroprotective effects. It is currently being investigated as a possible treatment for diseases characterized by neurodegeneration - particularly Alzheimer's disease.